M Cattaneo - Expert review of cardiovascular therapy, 2007 - ingentaconnect.com † Author for correspondence Università degli Studi di Milano, Unità di
Ematologia e Trombosi - Ospedale San Paolo, Via di Rudinì 8 20142 Milano, Italy
Tel.: +39 025 032 3095 marco.cattaneo@unimi.it Cited by 34 - Related articles - All 5 versions
- ►chestpubs.org M Sobel, R Verhaeghe - Chest, 2008 - chestjournal.chestpubs.org This chapter is devoted to antithrombotic therapy for peripheral artery
occlusive disease as part of the American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 ... Cited by 28 - Related articles - All 15 versions
- ►ahajournals.org NK Choudhry, AR Patrick, EM Antman, J … - Circulation, 2008 - Am Heart Assoc Methods and Results— We created a Markov cost-effectiveness model to estimate
the incremental cost-effectiveness of providing Medicare beneficiaries with full
coverage for combination pharmacotherapy compared with current coverage ... Cited by 25 - Related articles - All 8 versions
- ►hematologylibrary.org AA Hassan, MH Kroll - Hematology, 2005 - asheducationbook.hematologylibrary.org A qualitative abnormality of platelet function should be considered in patients
with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand
disease. Antiplatelet drugs are the most common cause of acquired platelet ... Cited by 21 - Related articles - All 3 versions
EN Liberopoulos, MS Elisaf, AD Tselepis, A … - Platelets, 2006 - informahealthcare.com A large number of patients require antiplatelet therapy (mainly aspirin and/or
clopidogrel). Recent studies suggest that the combination of these agents is
useful in patients with acute coronary syndrome and after percutaneous ... Cited by 18 - Related articles - BL Direct - All 8 versions
JW Cheng, MPH PharmD - Journal of Managed Care Pharmacy JMCP, 2007 - rotapharm.ru BACkgrounD: When used as an alternative to or in addition to aspirin,
clopidogrel has been demonstrated by some but not all randomized controlled
trials to be effective in secondary prevention of cardiovascular (CV) ... Cited by 10 - Related articles - View as HTML - BL Direct - All 11 versions
- ►nih.gov [PDF] DP Faxon, RW Nesto - Journal of the National Medical Association, 2006 - pubmedcentral.nih.gov Atherothrombosis is the most common cause of an acute ischemic event.
Antiplatelet agents form the cornerstone of atherothrombosis prevention. The
purpose of this article is to review the use of antiplatelet agents in ... Cited by 11 - Related articles - BL Direct - All 5 versions
